Iovance Biotherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY Revenue (est.)
$399.8Mnext fiscal year
FY EPS (est.)
-$0.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Amtagvi Product Revenue Quarterly60.2MTarget: 79000000 to 81000000
Total Product Revenue Annually71.4MTarget: 350000000 to 370000000
Activated Authorized Treatment Centers (ATCs) Annually
Watch Items
- Amtagvi Global Regulatory ApprovalsTrigger: Australian TGA approval achieved in June 2026; Swissmedic decision expected in H1 2027Action: Monitor commercial launch preparation in Australia and regulatory progress in Switzerland.
- Iovance Cell Therapy Center (iCTC) Manufacturing CapacityTrigger: Successful facility expansion completed to prevent future maintenance-related supply constraintsAction: Track gross margin improvements and manufacturing turnaround times.
Research as of 19 Jun 2026